# Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

> **NCT00002109** · PHASE3 · COMPLETED · sponsor: **Immunobiology Research Institute**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Thymopentin
- **DRUG:** Stavudine
- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002109
- **Lead sponsor:** Immunobiology Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002109, "Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*